Dr. Mylin A. Torres, Winship Cancer Institute

During my residency at the University of Texas MD Anderson Cancer Center, I received extensive training in radiotherapy. I have been involved in a number of published research studies assessing and evaluating ways to minimize radiotherapy side effects. I was recruited to the Department of Radiation Oncology at Emory University School of Medicine to lead the breast radiation oncology clinical and research program. At Emory, I have had the opportunity to treat a large number of breast cancer patients and develop an integrated program of multi-disciplinary research dedicated to understanding the pathophysiologic mechanisms underlying cancer therapy-related toxicities and to developing interventions for antagonizing these pathways. My expertise is in interpretation of biomarkers and genomic assays as they relate to cancer treatment and outcomes and behavioral symptoms, including fatigue and depression, in breast cancer patients. I have a strong interest in translating many of the bench side observations to the clinic and have participated in conducting many prospective, longitudinal studies with Drs. Miller and Conneely (co-Investigators) in breast cancer aimed at understanding biomarkers of treatment-related toxicities, evaluating therapeutic interventions for ameliorating such toxicities, and conducting multi-institutional trials to determine safety and efficacy of new treatments to enhance cancer control in metastatic breast cancer patients. As Glenn Family Breast Center Director for three years, I worked on in establishing infrastructure to conduct research and clinical trials. As now Co-Leader of the Cancer Prevention and Control Research Program, I am heavily involved in studies which impact our state and catchment area. Among U.S. metropolitan areas, Atlanta was recently found to have the largest disparities in breast cancer outcomes with black women doing significantly worse than white women. To address this problem within our community, I have conducted many clinical trials and research studies, including those with Drs. McCullough and Ward (co-I), addressing disparities in breast cancer outcomes and clinical trial enrollment. I have also recently worked with Dr. Banerjee (co-I) on the use of social media to capture patient reported outcomes not routinely recorded in the medical record. The proposed research involving Emory, Grady, and Phoebe Putney Health is a natural extension of my experience and collaborations I have developed with researchers at Emory and clinicians within our community over the last eleven years. We will examine patient level, lifestyle and behavioral factors, tumor, treatment, epigenetic changes, inflammation and inflammation-associated outcomes to improve our understanding of racial and geographic disparities observed in Georgia breast cancer patients assessed longitudinally with repeated measures.